[HTML][HTML] Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2023 - nature.com
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
Relapsed/refractory diffuse large B-cell lymphoma
JW Friedberg - Hematology 2010, the American Society of …, 2011 - ashpublications.org
Despite overall improvements in outcomes of diffuse large B-cell lymphoma (DLBCL),
approximately one-third of patients will develop relapsed/refractory disease that remains a …
approximately one-third of patients will develop relapsed/refractory disease that remains a …
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Background Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few
treatment options. We aimed to establish the safety and recommended phase 2 dose of …
treatment options. We aimed to establish the safety and recommended phase 2 dose of …
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell …
M Crump, J Kuruvilla, S Couban… - Journal of Clinical …, 2014 - ascopubs.org
Purpose For patients with relapsed or refractory aggressive lymphoma, we hypothesized
that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as …
that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as …
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
C Gisselbrecht, B Glass, N Mounier… - Journal of Clinical …, 2010 - ascopubs.org
Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell
transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma …
transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma …
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
G Iacoboni, G Villacampa, N Martinez‐Cibrian… - Cancer …, 2021 - Wiley Online Library
Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult …
MS Aapro, J Bohlius, DA Cameron, L Dal Lago… - European journal of …, 2011 - Elsevier
Chemotherapy-induced neutropaenia is a major risk factor for infection-related morbidity
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
ED Jacobsen, JP Sharman, Y Oki… - Blood, The Journal …, 2015 - ashpublications.org
Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma
(DLBCL), variably express CD30. This phase 2, open-label study evaluated the efficacy of …
(DLBCL), variably express CD30. This phase 2, open-label study evaluated the efficacy of …
Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study
GW Van Imhoff, A McMillan, MJ Matasar… - Journal of clinical …, 2017 - ascopubs.org
Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination
with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by …
with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by …
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
C Gisselbrecht, E Van Den Neste - British journal of …, 2018 - Wiley Online Library
Despite progress in the upfront treatment of diffuse large B cell lymphoma (DLBCL), patients
still experience relapses. Salvage chemotherapy followed by autologous stem cell …
still experience relapses. Salvage chemotherapy followed by autologous stem cell …